BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 25373692)

  • 1. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
    Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
    Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care.
    Pettit N; Boadu D; Bischof JJ
    Am J Emerg Med; 2021 Dec; 50():5-9. PubMed ID: 34265732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
    Pherwani N; Ghayad JM; Holle LM; Karpiuk EL
    Am J Health Syst Pharm; 2015 Apr; 72(8):619-31. PubMed ID: 25825185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
    Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
    Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
    Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
    Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia.
    Lalami Y; Paesmans M; Aoun M; Munoz-Bermeo R; Reuss K; Cherifi S; Alexopoulos CG; Klastersky J
    Support Care Cancer; 2004 Oct; 12(10):725-30. PubMed ID: 15235901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
    Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
    J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].
    Cervetti L; Vallard A; Le Moulec S; Espenel S; Falk AT; Ben Mrad M; Guy JB; Diao P; Méry B; Langrand-Escure J; Ferrand FR; Rivoirard R; Ceccaldi B; Védrine L; Magné N; Chargari C
    Bull Cancer; 2016 Jun; 103(6):561-70. PubMed ID: 27181759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of infection, therapy, outcome and risk stratification of patients with febrile neutropenia in a tertiary care oncology hospital in India.
    Noronha V; Joshi A; Patil VM; Bhosale B; Muddu VK; Banavali S; Kelkar R; Prabhash K
    Indian J Cancer; 2014; 51(4):470-4. PubMed ID: 26842166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
    Ahn S; Lee YS; Lim KS; Lee JL
    Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
    Nguyen M; Jacobson T; Torres J; Wann A
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?
    Moon H; Choi YJ; Sim SH
    PLoS One; 2018; 13(12):e0210019. PubMed ID: 30596803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department.
    Keng MK; Thallner EA; Elson P; Ajon C; Sekeres J; Wenzell CM; Seastone DJ; Gallagher EM; Weber CM; Earl MA; Mukherjee S; Pohlman B; Cober E; Foster VB; Yuhas J; Kalaycio ME; Bolwell BJ; Sekeres MA
    J Oncol Pract; 2015 Nov; 11(6):450-5. PubMed ID: 26220930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
    Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
    Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of ED and direct admission care of cancer patients with febrile neutropenia.
    Owolabi DK; Rowland R; King L; Miller R; Hegde GG; Shang J; Lister J; Venkat A
    Am J Emerg Med; 2015 Jul; 33(7):966-9. PubMed ID: 25959844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey.
    André S; Taboulet P; Elie C; Milpied N; Nahon M; Kierzek G; Billemont M; Perruche F; Charpentier S; Clément H; Pourriat JL; Claessens YE
    Crit Care; 2010; 14(2):R68. PubMed ID: 20403164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.